Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.55 |
| ▸ | SYK | P43405 | 13/20 | 0.44 |
| ▸ | CD63 | P08962 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478244 | 0.79 | AURKA (0.56) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL5478247 | 0.78 | AURKA (0.61) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL5479137 | 0.76 | AURKA (0.59) | AURKASYKBTK | |
| SCHEMBL2478983 | 0.68 | SYK (0.75) | SYKCD63 | |
| SCHEMBL2482275 | 0.67 | AURKA (0.79) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL13337418 | 0.67 | SYK (0.64) | AURKASYKCD63 | |
| SCHEMBL5478486 | 0.66 | AURKA (0.78) | AURKASYKBTK | |
| SCHEMBL1592216 | 0.66 | CYP2D6 (0.44) | FLT3BTK | |
| SCHEMBL5482196 | 0.65 | AURKA (0.79) | AURKASYKBTK | |
| Hydrochloric Acid SCHEMBL4072493 | 0.64 | IKBKB (0.46) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288295-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, MAP3K1, PRKACA | AURKA 186/4885SYK 483/4885CD63 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.